2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1982

Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
Abstract Number: 901

Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
Abstract Number: 666

Sensitivity to Change of the Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) Measures in a Single Canadian Lupus Cohort
Abstract Number: 1660

Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Abstract Number: 103

Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
Abstract Number: 102

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)
Abstract Number: 2116

Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Abstract Number: 1901

Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Abstract Number: 656

Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis
Abstract Number: 882

Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Abstract Number: 1888

Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Abstract Number: 973

Serum IgG4 Concentrations Differ According to Race and Sex
Abstract Number: 1834

Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Abstract Number: 2913

Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Abstract Number: 467

Serum Long-chain n-3 and -6 Fatty Acids Are Associated with Disease Feature at Onset and with 6-month Disease Activity in Early RA: Results from the ESPOIR Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].